The global angioplasty balloons and stents market is estimated to grow at a CAGR of 3.67% during the forecast period from 2024 to 2030. The demand for angioplasty balloons and stents is primarily being boosted by the increasing number of people with cardiovascular diseases (CVDs), the rise in demand for minimally invasive procedures, growing innovations in drug-coated/drug-eluting balloons, and others. Furthermore, the angioplasty balloons and stents market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the angioplasty balloons and stents market during the forecast period from 2024-2030.
As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men. As per the same source, in 2019, in North America, cardiovascular diseases affected 4,103,135 people, 1,089,947 people were diagnosed with coronary artery disease, and 498,551 suffered from stroke; In Asia, there were 32,376,834 people diagnosed with cardiovascular diseases, from which 12,543,833 individuals were affected by coronary artery disease, and 8,111,044 population was suffered from a stroke.
The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.
The increasing number of risk factors such as obesity, hypertension, diabetes, smoking, old age, alcohol consumption, unhealthy lifestyle, atherosclerosis, and others causing the development of cardiovascular diseases in one way or another are further going to accelerate the market for angioplasty balloons and stents.
According to the data provided by the WHO (2022), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people.
As per research studies, the prevalence of PAD increases with age; it occurs in 3% of people < 60 years, but its prevalence increases to 15% to 20% among individuals >70 years.
Thus, owing to the above-mentioned factors, the angioplasty balloons and stents market is estimated to grow during the forecast period.
However, stringent regulatory procedures adverse effects, and product recalls may restrict the growth of the overall angioplasty balloons and stents market.
In the product type segment under the balloons category of the Angioplasty Balloons and Stents market, the drug-coated balloons, category is expected to amass a significant revenue share in the year 2023.
The advantages and applications associated with drug-coated balloons in the treatment of coronary artery disease and peripheral artery disease are going to increase their demand.
Procedure-wise, Drug-Coated Balloon (DCB) angioplasty is comparable to Plain Old Balloon Angioplasty (POAB), but it includes coating the balloon with an anti-proliferative medicine and an excipient to facilitate drug transfer.
Drug-coated balloons aid in the prevention of restenosis, which is the vessel's re-narrowing at a previously treated spot. Employing a balloon coated with medication may prevent cell division, thereby reducing the degree of restenosis, or blockage regrowth, following therapy.
By not implanting a foreign body during the DCB angioplasty, the patient's body is spared from modifications to the coronary artery's original anatomical structure as well as risks such as late stent thrombosis and allergy.
Additionally, it offers chances for further surgical treatment or interventional therapy, especially for young patients.
The interventional process is comparatively easy, requiring less time to complete and exposing patients and medical personnel to less radiation.
By uniformly distributing the medication to the blood vessel's inner wall, DCB can prevent the delayed endothelialization brought on by the unequal dispersion of stent metal rods.
By applying DCB, the duration of dual antiplatelet medication can be shortened, and the risk of bleeding and other problems can be decreased.
For certain kinds of lesions, such as narrow lesions, high bleeding risk lesions, patients with diabetes, etc., DCB may be a better option than stent insertion.
Thus, all the above-mentioned factors are likely to propel the market for drug-coated balloons in Angioplasty Balloons and Stents.
For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) in 2023, it was stated that in 2021, about 1 in 20 adults age 20 and older have coronary artery disease (CAD). Coronary heart disease is the most common type of heart disease in the US, killing 375,476 people in 2021. In 2021, about 2 in 10 deaths from CAD happened in adults less than 65 years old. Thus, the high burden of cardiovascular diseases in the region demands the availability of drug-eluting balloons.
The American Heart Association in the latest study estimated that over 500,000 percutaneous coronary intervention (PCI) procedures are carried out annually in the US. Percutaneous coronary intervention with a drug-coated balloon (DCB) is a novel treatment that seeks to acutely dilate coronary stenosis and deliver an anti-proliferative drug to the vessel wall. Thus, the number of PCI procedures in the region will increase the demand for drug-eluting balloons.
Further, the availability of various major manufacturers, the launch and approval of new and technologically advanced devices, and favorable reimbursement regulations are all important factors responsible for driving the demand for drug-eluting balloons in the region. For instance, in November 2022, Genesis MedTech Group announced that the Food and Drug Administration (FDA) has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery.
Thus, the above-mentioned factors are likely to propel the growth of the angioplasty balloons and stents market in the region during the forecast period from 2024-2030.
This product will be delivered within 2 business days.
Angioplasty Balloons And Stents Market Dynamics:
According to American Heart Association 2022 data, globally about 244.1 million people were living with coronary (ischemic) heart disease in 2020.As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men. As per the same source, in 2019, in North America, cardiovascular diseases affected 4,103,135 people, 1,089,947 people were diagnosed with coronary artery disease, and 498,551 suffered from stroke; In Asia, there were 32,376,834 people diagnosed with cardiovascular diseases, from which 12,543,833 individuals were affected by coronary artery disease, and 8,111,044 population was suffered from a stroke.
The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.
The increasing number of risk factors such as obesity, hypertension, diabetes, smoking, old age, alcohol consumption, unhealthy lifestyle, atherosclerosis, and others causing the development of cardiovascular diseases in one way or another are further going to accelerate the market for angioplasty balloons and stents.
According to the data provided by the WHO (2022), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people.
As per research studies, the prevalence of PAD increases with age; it occurs in 3% of people < 60 years, but its prevalence increases to 15% to 20% among individuals >70 years.
Thus, owing to the above-mentioned factors, the angioplasty balloons and stents market is estimated to grow during the forecast period.
However, stringent regulatory procedures adverse effects, and product recalls may restrict the growth of the overall angioplasty balloons and stents market.
Angioplasty Balloons And Stents Market Segment Analysis:
Angioplasty Balloons and Stents Market By Product Type (Balloons [Drug-Coated Balloons and Plain Old Balloons], Stents [Drug-Eluting Stents and Bare Metal Stents]), Indication (Coronary Artery Disease and Peripheral Artery Disease), End-User (Hospitals, Ambulatory Surgical Centers, and Cath Labs), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)In the product type segment under the balloons category of the Angioplasty Balloons and Stents market, the drug-coated balloons, category is expected to amass a significant revenue share in the year 2023.
The advantages and applications associated with drug-coated balloons in the treatment of coronary artery disease and peripheral artery disease are going to increase their demand.
Procedure-wise, Drug-Coated Balloon (DCB) angioplasty is comparable to Plain Old Balloon Angioplasty (POAB), but it includes coating the balloon with an anti-proliferative medicine and an excipient to facilitate drug transfer.
Drug-coated balloons aid in the prevention of restenosis, which is the vessel's re-narrowing at a previously treated spot. Employing a balloon coated with medication may prevent cell division, thereby reducing the degree of restenosis, or blockage regrowth, following therapy.
By not implanting a foreign body during the DCB angioplasty, the patient's body is spared from modifications to the coronary artery's original anatomical structure as well as risks such as late stent thrombosis and allergy.
Additionally, it offers chances for further surgical treatment or interventional therapy, especially for young patients.
The interventional process is comparatively easy, requiring less time to complete and exposing patients and medical personnel to less radiation.
By uniformly distributing the medication to the blood vessel's inner wall, DCB can prevent the delayed endothelialization brought on by the unequal dispersion of stent metal rods.
By applying DCB, the duration of dual antiplatelet medication can be shortened, and the risk of bleeding and other problems can be decreased.
For certain kinds of lesions, such as narrow lesions, high bleeding risk lesions, patients with diabetes, etc., DCB may be a better option than stent insertion.
Thus, all the above-mentioned factors are likely to propel the market for drug-coated balloons in Angioplasty Balloons and Stents.
North America is expected to dominate the overall Angioplasty Balloons And Stents Market:
Among all the regions, North America is estimated to account for the largest share of the Angioplasty Balloons and Stents market in the year 2023. This domination is due to the increasing application of angioplasty balloons and stents in the treatment and management of peripheral and coronary artery disease which are on the rise in the region, increasing sedentary lifestyle, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases, rising product launch and approvals, presence of favorable regulatory authority, among others will propel the market of angioplasty balloons and stents in the US.For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) in 2023, it was stated that in 2021, about 1 in 20 adults age 20 and older have coronary artery disease (CAD). Coronary heart disease is the most common type of heart disease in the US, killing 375,476 people in 2021. In 2021, about 2 in 10 deaths from CAD happened in adults less than 65 years old. Thus, the high burden of cardiovascular diseases in the region demands the availability of drug-eluting balloons.
The American Heart Association in the latest study estimated that over 500,000 percutaneous coronary intervention (PCI) procedures are carried out annually in the US. Percutaneous coronary intervention with a drug-coated balloon (DCB) is a novel treatment that seeks to acutely dilate coronary stenosis and deliver an anti-proliferative drug to the vessel wall. Thus, the number of PCI procedures in the region will increase the demand for drug-eluting balloons.
Further, the availability of various major manufacturers, the launch and approval of new and technologically advanced devices, and favorable reimbursement regulations are all important factors responsible for driving the demand for drug-eluting balloons in the region. For instance, in November 2022, Genesis MedTech Group announced that the Food and Drug Administration (FDA) has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery.
Thus, the above-mentioned factors are likely to propel the growth of the angioplasty balloons and stents market in the region during the forecast period from 2024-2030.
Angioplasty Balloons And Stents Market Key Players:
Some of the key market players operating in the Angioplasty Balloons and Stents market include B. Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors International Group, Ltd., MicroPort Scientific Corporation, Terumo Corporation, Demax Medical Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept Medical, and Others.Recent Developmental Activities in the Angioplasty Balloons And Stents Market:
- In January 2023, The US Food and Drug Administration (FDA) approved the Stellarex 0.035” OTW Drug-coated Angioplasty Balloon - P160049/S015, from Philips Image Guided Therapy Corp.
- In August 2019, B. Braun Interventional Systems Inc. (BIS) announced that the US Food and Drug Administration (FDA) granted Breakthrough Device Designation for the SeQuent Please ReX drug-coated PTCA balloon catheter.
Key Takeaways from the Angioplasty Balloons And Stents Market Report Study
- Market size analysis for current angioplasty balloons and stents market size (2023), and market forecast for 6 years (2024-2030)
- Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the global Angioplasty Balloons and Stents market.
- Various opportunities available for the other competitors in the Angioplasty Balloons and Stents market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030?
- Which are the top-performing regions and countries in the current Angioplasty Balloons and Stents market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for Angioplasty Balloons and Stents market growth in the coming future?
Target Audience who can be benefited from this Angioplasty Balloons And Stents Market Report Study
- Angioplasty Balloons and stent product providers
- Research organizations and consulting companies
- Angioplasty Balloons and Stents-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in Angioplasty Balloons and Stents
- Various End-users who want to know more about the Angioplasty Balloons and Stents market and the latest developments in the Angioplasty Balloons and Stents market.
Frequently Asked Questions for the Angioplasty Balloons And Stents Market:
1. What are angioplasty balloons and stents?
Angioplasty Balloons and Stents are intended for the effective treatment of coronary and peripheral artery disease by opening a narrowed or blocked artery.2. What is the market for global Angioplasty Balloons and Stents?
The global angioplasty balloons and stents market is estimated to grow at a CAGR of 3.67% during the forecast period from 2024 to 2030.3. What are the drivers for the global angioplasty balloons and stents market?
The demand for angioplasty balloons and stents is primarily being boosted by the increasing number of people with cardiovascular diseases (CVDs), the rise in demand for minimally invasive procedures, growing innovations in drug-coated/drug-eluting balloons, and others. Furthermore, the angioplasty balloons and stents market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the angioplasty balloons and stents market during the forecast period from 2024-2030.4. Who are the key players operating in the global angioplasty balloons and stents market?
Some of the key market players operating in the angioplasty balloons and stents market include B. Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors International Group, Ltd., MicroPort Scientific Corporation, Terumo Corporation, Demax Medical Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept Medical, and Others.5. Which region has the highest share in the angioplasty balloons and stents market?
North America is expected to dominate the overall Angioplasty Balloons and Stents market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the increasing patient pool with peripheral and coronary artery disease, increasing sedentary lifestyle, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases. Further, rising product launches and approvals and, the presence of favorable regulatory authority, among others will propel the market of angioplasty balloons and stents in the US.This product will be delivered within 2 business days.
Table of Contents
1. Angioplasty Balloons and Stents Market Report Introduction8. KOL Views9. Project Approach10. Publisher Capabilities11. About the Publisher12. Disclaimer
2. Angioplasty Balloons and Stents Market Executive Summary
3. Regulatory Analysis
4. Angioplasty Balloons and Stents Market Key Factors Analysis
5. Angioplasty Balloons and Stents Market Porter’s Five Forces Analysis
6. Angioplasty Balloons and Stents Market Layout
7. Angioplasty Balloons and Stents Market Company and Product Profiles
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- B. Braun SE
- BIOTRONIK
- Medtronic
- Abbott
- Boston Scientific Corporation
- Cook
- Biosensors International Group, Ltd.
- MicroPort Scientific Corporation
- Terumo Corporation
- Demax Medical Technology
- BD
- BrosMed Medical Co., Ltd.
- Cordis
- Sino Medical Sciences Technology Inc.
- Concept Medical